Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9.
Jacobson O, Zhang HH, Olkowski CP, Ghaemi B, Basuli F, Shi J, Bell MM, Parween F, Ganesan S, Esparza TJ, Escorcia FE, Choyke PL, Farber JM.
Jacobson O, et al.
J Nucl Med. 2025 Sep 2;66(9):1372-1377. doi: 10.2967/jnumed.125.269795.
J Nucl Med. 2025.
PMID: 40813232
Free PMC article.
In xenograft models, [(18)F]F-h2A12 showed significant uptake in CXCL9-expressing tumors (10.33 1.23 %IA/g) compared with control tumors (0.25 0.04 %IA/g) at 2 h after injection, with excellent tumor-to-background ratios. In the humanized model, T-cell engager therapy …
In xenograft models, [(18)F]F-h2A12 showed significant uptake in CXCL9-expressing tumors (10.33 1.23 %IA/g) compared with control tumors ( …